PT  - JOURNAL ARTICLE
AU  - Yoshihara, Tatsuya
AU  - Ito, Kazuya
AU  - Zaitsu, Masayoshi
AU  - Chung, Eunhee
AU  - Aoyagi, Izumi
AU  - Kaji, Yoshikazu
AU  - Tsuru, Tomomi
AU  - Yonemura, Takuma
AU  - Yamaguchi, Koji
AU  - Nakayama, Shinichi
AU  - Tanaka, Yosuke
AU  - Yurino, Nobuo
AU  - Koyanagi, Hideki
AU  - Matsuki, Shunji
AU  - Urae, Ryuji
AU  - Irie, Shin
TI  - SARS-CoV-2 seroprevalence among healthcare workers in general hospitals and clinics in Japan
AID  - 10.1101/2021.01.23.21249922
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.23.21249922
4099  - http://medrxiv.org/content/early/2021/01/25/2021.01.23.21249922.short
4100  - http://medrxiv.org/content/early/2021/01/25/2021.01.23.21249922.full
AB  - Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. However, little is known about the prevalence of COVID-19 among healthcare workers in Japan. We aimed to examine the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2,160 healthcare workers in general hospitals and clinics in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in August and October 2020, which is relatively higher than that in the general population in Japan. Because of the higher risk of COVID-19 infection, healthcare workers should be the top priority for further social support and vaccination against SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUMIN000041262Funding StatementThis study did not receive external funding. The immunochromatographic assay kits used in this study were provided by SoftBank Group Corp.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SOUSEIKAI Hakata Clinic Institutional Review Board (Approval number: N-105)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, TY, upon reasonable request, according to the Ethical Guidelines for Medical and Health Research Involving Human Subjects, Japan.